Somerset Partnership Seeks to Increase Patient Participation in Clinical Trials with TriNetX
LONDON, April 25, 2018 /PRNewswire/ -- Somerset Partnership NHS Foundation Trust, which serves a patient population of 650,000 in the south west region of the U.K., is the first integrated mental and community health trust in the NHS to join TriNetX, with the goal of expanding the participation of its patients in clinical trials.
"Our involvement with TriNetX is about providing patients with the opportunity to take part in research," said Andrew Harewood, Head of Research and Clinical Effectiveness at Somerset Partnership. Part of the NIHR Clinical Research Network: South West Peninsula, Somerset Partnership is actively involved in a number of studies covering a range of specialties including mental health, community health, learning disabilities, diabetes, and stroke, among others. "TriNetX gives us the ability to actually analyse and interrogate our own data in a way that enables us to invite more people to be involved."
Researchers from Somerset Partnership, in conjunction with the local National Institute for Health Research Clinical Research Network and regional counterparts, recognised the benefit of harnessing TriNetX to establish a number of collaborative research networks; initially spanning all secondary care organisations within the south west to maximise strategic research capabilities, opportunities and enable improved patient choice and outcomes.
TriNetX offers the fastest growing collaborative network of over 70 healthcare organisations representing hundreds of facilities across 11 countries. TriNetX has presented over 1,500 clinical trial opportunities to its healthcare members.
Network members utilise TriNetX's cloud-based, health research platform to analyse patient populations and perform "what-if" analyses in real-time. As members, healthcare organisations are provided, at no cost to themselves, with all of the hardware, software and services that are needed to integrate with the TriNetX platform. TriNetX's unique integration methodology minimises impact to the member's local IT resources and ensures a rapid and compliant approach, often building on existing data resources such as i2b2 and Observational Medical Outcomes Partnership (OMOP). Researchers then have access to the institution's de-identified patient data through a user-friendly interface and a growing number of visualisation and analysis capabilities.
Biopharmaceutical companies and CROs are presented with aggregate views, but each data point in the TriNetX network can be traced to healthcare organisations who have the ability to identify individual patients. This enables clinical researchers to develop virtual patient cohorts that can then be re-identified for potential recruitment into a clinical trial.
"We are extremely pleased and proud to have Somerset Partnership join as our first integrated mental and community health trust within the NHS and we look forward to not only helping them get more of their patients into clinical trials, but to also maximising the strategic research capabilities and opportunities across the whole south west via our unique collaborative research networks," said Steve Lethbridge, Vice President, EMEA at TriNetX. "We believe our growing network of healthcare organisations, biopharmaceutical companies, and CROs will help them achieve their goal."
About Somerset Partnership, NHS Foundation
Servicing a population of 650,000 and employing 3,500, Somerset Partnership consists of 13 community hospitals across the county, provides mental health community and inpatient services as well as numerous community health services for children and adults. They run 7 minor injury units and 4 dental access centres, including on the Isle of Wight and in Dorset. They make more than 1.1 million patient contacts each year. Somerset was authorised as a Foundation Trust in May 2008 and has more than 10,000 members and 33 governors. For further information, visit http://www.sompar.nhs.uk/.
About TriNetX
TriNetX is the global health research network enabling healthcare organisations, biopharma and contract research organisations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. Each member of our community shares in the consolidated value of our global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study. For more information, visit https://www.trinetx.com or follow @TriNetX on Twitter.
Media Contacts
Somerset Partnership, NHS Foundation
Victoria Eld
07887 947 423
victoria.eld@sompar.nhs.uk
Twitter: @SomParNHS
Jeff Stoecker
Racepoint Global
(518) 265-8370
trinetx@racepointglobal.com
Logo - https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg
Share this article